Cancer Institute of New Jersey (CINJ), Melanoma & Soft Tissue Oncology

Fingerprint Dive into the research topics where Cancer Institute of New Jersey (CINJ), Melanoma & Soft Tissue Oncology is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Safety Medicine & Life Sciences
Autophagy Medicine & Life Sciences
Riluzole Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1997 2024

Mitogen-Activated Protein Kinase Kinases
Melanoma
Apoptosis
Therapeutics
Disease-Free Survival
Neoplasms
Clinical Trials
Therapeutics
Systems Biology
Pharmacogenetics

CANCER CENTER SUPPORT GRANT

Kane, M., Zong, W., Mehnert, J., Manne, S., Delnevo, C., Shen, Z., Ganesan, S., Foran, D., Liu, C., Laskin, D., Shih, W., Aisner, J., Lattime, E., Haffty, B., Bertino, J., August, D., Goodin, S., Goodin, S., August, D., Laskin, D., Shih, W., Rabinowitz, J., Zheng, S., Sant'Angelo, D. B., Saunders, T., Tanzer, L. L., Gallo, J., Leibowitz, M., Chin, K. V., Ravikumar, T., Hait, W., Dipaola, R., Libutti, S. K., Kinzy, T. G., Spaulding, H., Amenta, P., Denicola, G., Shen, M. M., Kinzy, T. G., Notterman, D., Amenta, P. S., Rubin, E. H. & Cunningham, R. S.

National Institutes of Health

3/1/972/29/24

Project: Research project

Neoplasms
Research
Financial Management
Organized Financing
New Brunswick

Research Output 2002 2020

Association of Rising Cost and Use of Oral Anticancer Drugs with Medicare Part D Spending from 2013 Through 2017

Seiger, K., Mostaghimi, A., Silk, A. W., Schmults, C. D. & Ruiz, E. S., Jan 2020, In : JAMA Oncology. 6, 1, p. 154-156 3 p.

Research output: Contribution to journalLetter

Medicare Part D
Costs and Cost Analysis
Pharmaceutical Preparations
5 Citations (Scopus)

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.

Research output: Contribution to journalArticle

Melanoma
Neoplasms
Therapeutics
Disease-Free Survival
Survival
2 Citations (Scopus)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

Andtbacka, R. H. I., Amatruda, T., Nemunaitis, J., Zager, J. S., Walker, J., Chesney, J. A., Liu, K., Hsu, C. P., Pickett, C. A. & Mehnert, J. M., Sep 2019, In : EBioMedicine. 47, p. 89-97 9 p.

Research output: Contribution to journalArticle

Open Access
Oncolytic Viruses
Viruses
Melanoma
Occlusive Dressings
Blood